 | |
- close
- close
|
The Economic Times
9 hrs ago
Comment
Daiichi Sankyo is going to launch some of Ranbaxy's generic medicine in the Japanese market soon.
Business Standard
Nov 8
Comment
Leading Japanese drug maker Daiichi Sankyo has challenged the Securities Appellate Tribunal (SAT) judgement that asked it to make an open offer to shareholders of Zenotech Labs at Rs 160 per share.
The Economic Times
Nov 5
Comment
Daiichi Sankyo, has begun a late-stage trial in Japan for the influenza treatment laninamivir, a drug that aims to prevent new H1N1 flu.
The Economic Times
Nov 2
Comment
In what will finally bring an end to the year-long dispute between Daiichi Sankyo and the minority shareholders of Zenotech over the open offer price, the Supreme Court (SC) said it will have a final hearing of the case on December 2.
Business Standard
Oct 30
Comment
Japanese drug maker Daiichi Sankyo, which holds 64 per cent stake in Ranbaxy Laboratories, today reported a 45 per cent drop in net income for the April-September this year. The company has a net income of 18.69 billion for six months ended...
The Economic Times
Oct 30
Comment
Japanese drug maker Daiichi Sankyo, which holds 64 per cent stake in Ranbaxy Laboratories, today reported a 45 per cent drop in net income for April- September this year.
The Economic Times
Oct 28
Comment
Ranbaxy Laboratories and its Japanese parent Daiichi Sankyo are working on a three-year plan for exploiting synergies in operations to enhance their generic as well as branded business across the globe.
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
| ||||||
|
|
